Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
about
Inhaled Antibiotics for Gram-Negative Respiratory InfectionsTackling Drug Resistant Infection Outbreaks of Global Pandemic Escherichia coli ST131 Using Evolutionary and Epidemiological Genomics.Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patientsRecommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.Pulmonary penetration of piperacillin and tazobactam in critically ill patients.The evolution of the regulatory framework for antibacterial agentsDetermining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds.Design of clinical trials of antibacterial agents for community-acquired bacterial pneumoniaPharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineFrequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogensPharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniaeCeftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavagePenetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.Microbiological effects of sublethal levels of antibiotics.Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.Cost Drivers of a Hospital Acquired Bacterial Pneumonia and Ventilator Associated Bacterial Pneumonia (HABP/VABP) Phase Three Clinical Trial.Urinary Tract Infections: Resistance Is Futile.Determination of meropenem penetration into the lung from Sparse data.Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.Comparison of direct sampling and brochoalveolar lavage for determining active drug concentrations in the pulmonary epithelial lining fluid of calves injected with enrofloxacin or tilmicosin.Stepping Off the Resistance Treadmill.Model System Identifies Kinetic Driver of Hsp90 Inhibitor Activity against African Trypanosomes and Plasmodium falciparum
P2860
Q28386160-1A9DF923-68E3-4C08-8D9B-4FAE09B74F27Q30393531-5A53003A-69E9-48CE-A41E-32339F3DCFF4Q33752635-010D9FD1-B1A1-41B8-8B4A-FBDE6FF05081Q34165319-82AF025D-49CE-475A-9201-9F2A79A2C28BQ34216623-88AFD014-8BA6-407E-9AEF-B92CDE3E8242Q34693386-8FBF85E3-B54B-49AD-ADFE-3636BB0BE48BQ34739945-A5A386F4-0F51-4A7C-8475-0A629D4F45D3Q35215307-5BB11E40-0E5F-4CF4-9E2A-43E55FE6B3CCQ35689185-E8F7FC8D-B128-44C9-925B-3DEFA2013976Q35806456-D3B4F624-7BD2-4FDE-9809-9960E574F06CQ35867360-8B60AD18-99DF-43DF-AEC0-FD314C1D4FEAQ35905561-BDA1A154-C5FF-403C-A7D2-0852D6E3F50DQ36083619-1A5FE5C3-D6B5-4502-B3CB-1687CF16AE61Q36276911-E94ABAE7-5008-4160-8FB5-48C374E77CA2Q36290773-F29F8B17-4CE6-45FE-923C-2B00CC2A0901Q36757628-437BB825-F28B-48B0-91B3-D19D268FF711Q36854025-35E59779-031A-42DE-875B-CFF2D3AFBA97Q37023175-34A93392-4DED-4EEF-ABAA-5C3863D9B44FQ37308807-863BCF0B-370E-4836-9BA9-39638C0B6798Q37538724-CC24A861-89E4-4FE4-99FA-2507AFA6E030Q37544570-DAB285D1-E06A-48C0-9503-B21B9BE26495Q37927017-02BDB402-B15A-4D8C-AD87-76541D4091D4Q38138835-747161BD-6306-4FBA-A2D6-FFA9D2E6D553Q38171760-DF1DA159-A0C4-4985-9449-447B175C984BQ38214805-E72CE0D5-7D08-444C-8818-8969313EC1E1Q38605120-EEE87950-FA4A-4DCE-AC83-596421F8A318Q38644824-67ED460B-7F18-44D8-865B-29D3A1B02AB4Q40140013-6B536550-A1E7-46A2-B22A-28B1DADF6C3CQ41987099-4D530FF9-CDB0-437E-8E0F-E4D2EBC166DBQ42934108-27FD5C87-C0F5-4FE6-943E-1129560450F2Q43005046-782D6443-8A58-4341-9D9C-3814A587D941Q45289238-E7A000E5-7886-4872-99A3-FB5CF3BEB6BFQ47037063-5B4C3C9B-0FFE-427A-AC8F-AC366EF30BE5Q53311081-7EDCC4F9-323F-4BD5-A992-76385E9E358FQ56355675-526ACAD5-0E23-4588-AAD5-9DFB494B234F
P2860
Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetic-pharmacodynami ...... studies: look before you leap!
@en
Pharmacokinetic-pharmacodynami ...... studies: look before you leap!
@nl
type
label
Pharmacokinetic-pharmacodynami ...... studies: look before you leap!
@en
Pharmacokinetic-pharmacodynami ...... studies: look before you leap!
@nl
prefLabel
Pharmacokinetic-pharmacodynami ...... studies: look before you leap!
@en
Pharmacokinetic-pharmacodynami ...... studies: look before you leap!
@nl
P2093
P356
P1476
Pharmacokinetic-pharmacodynami ...... studies: look before you leap!
@en
P2093
Evelyn J Ellis-Grosse
George L Drusano
Paul G Ambrose
Sujata M Bhavnani
P304
P356
10.1086/653057
P407
P478
51 Suppl 1
P577
2010-08-01T00:00:00Z